Acute kidney injury (AKI) causes severe morbidity and mortality for which new therapeutic strategies are needed. Docosahexaenoic acid (DHA), arachidonic acid (ARA), and their metabolites have various effects in kidney injury, but their molecular mechanisms are largely unknown. Here, we report that 14 (15)-epoxyeicosatrienoic acid [14 (15) A cute kidney injury (AKI) is globally highly prevalent with an incidence varying from 140 to 2,880 per million people (1) . AKI is common in hospitalized patients, increasing with the severity of morbidity. The incidence of AKI in hospitalized patients increased dramatically from 4.9% in 1983 (2) to 20% in 2012 (3) . The mortality from AKI is greater than 50%, equaling approximate 2 million people dying of AKI every year worldwide (1) . Although AKI is common and often devastating, in some cases AKI is preventable and treatable (4) . A goal was announced by the Lancet/International Society of Nephrology Commission to achieve zero preventable deaths from AKI by 2025 (5) . Therefore, novel, safe, and effective approaches are urgently needed to prevent and treat AKI. Docosahexaenoic acid (DHA) and DHA-enriched fish oil were found to ameliorate kidney injury prophylactically and therapeutically in multiple animal models (6) (7) (8) (9) . However, the mechanism underlying the reno-protection of DHA remains uncertain. Evidence supports that the metabolites of DHA contribute to its effect profile profoundly. Recently, we found that epoxydocosapentaenoic acids (EDPs), the epoxide metabolites of DHA, inhibit angiogenesis, tumor growth, and metastasis in murine models (10) . DHA, presumably through its epoxide metabolites EDPs, lowers blood pressure in hypertensive mice (11) . Sharma et al. (12) reported recently that 19 (20)-EDP significantly reduced renal fibrosis in a murine model of uremia. However, the effects of EDP on AKI remain unknown. In addition, pharmacological intervention with the inhibitors of soluble epoxide hydrolase (sEH) and target gene disruption of sEH were reported to be renoprotective in murine and rodent models of AKI, which may be involved in down-regulation of nuclear factor-κB (13) (14) (15) , implying that the epoxides of polysaturated fatty acids (PUFAs) such as epoxyeicosatrienoic acids (EETs), the substrates of sEH, may attenuate AKI. However, no distinct evidence has been presented to show the reno-protective effect of any specific epoxide metabolite of PUFAs like EETs or EDPs. Therefore, here we report the effects of a major EDP and EET regiosiomer on kidney injury in a murine model of ischemia/reperfusion (I/ R)-caused AKI by direct administration.
In addition, glycogen synthase kinase 3β (GSK3β), a 47-kDa serine-threonine kinase, is a therapeutic target for AKI (16) . Both hypoxia-induced apoptosis in vascular smooth muscle cells and COS-7 cells and cisplatin-caused injury in renal tubular cells
Significance
This study demonstrates that 19 (20)-EDP, the major epoxide metabolite of ω-3 polyunsaturated fatty acid (PUFA) docosahexaenoic acid, aggravates while 14 (15)-EET, the major epoxide metabolite of ω-6 PUFA arachidonic acid, alleviates acute kidney injury (AKI) in a murine model. The metabolite 19 (20)-EDP significantly shortened while 14 (15)-EET significantly prolonged the survival of AKI mice. Opposite effects of the EDP and EET regioisomers in ischemia/reperfusion-caused kidney injury may partially account for the opposite effects of 14 (15)-EET and 19 (20) -EDP in modulation of the hypoxia/reoxygenation-caused apoptosis of renal tubular epithelial cells and the phosphorylation of GSK3β, a promising therapeutic target for AKI. However, our study provides a caution regarding the use of dietary ω-3 fatty acids in renal injury.
were accompanied by a significant reduction in phosphorylated GSK3β (p-GSK3β), resulting in an increase in GSK3β activity in vitro (17, 18) . Similar changes in GSK3β and p-GSK3β were also observed in I/R-and cisplatin-caused kidney injury in animal models of AKI, and inhibition of GSK3β was found to reverse the changes and attenuate the kidney injury (17, 18) . However, the role of GSK3β and its phosphorylation in the function of PUFA epoxides in kidney injury and repair has not been reported. Here, we report that the effects of the major regioisomers of EDP and EET on AKI are involved in the modulation of GSK3β phosphorylation. (20)-EDP with TPPU resulted in wider renal tubules and more detachment of the tubular brush border than those of AKI mice, exacerbating the I/R-caused renal injury visually. In particular, the histological examination for the kidneys from the dead mice showed obviously severe injury.
Results
As illustrated in Fig. 2A , I/R-caused AKI mice had a significantly higher plasma level of creatinine (Cr) than those of sham mice. The administration of 19 (20) The renal levels of NGAL in the mice dead 24 h post treatment were much higher than those of sham mice, which were beyond the upper limit of the quantitation for the method.
TPPU Stabilized and MS-PPOH Suppressed the Epoxide Levels in Vivo.
As shown in Fig. 2 D and E and SI Appendix, Table S1 , treatment with TPPU significantly stabilized the plasma levels of epoxides like EETs and EDPs. When TPPU was coadministered with 14 (15) Table S1 ).
Coadministration of MS-PPOH with DHA Enhanced the Reno-Protective
Effect of DHA. As expected, the administration of DHA alone resulted in the reduction in plasma Cr (6.97 ± 0.88 vs. 9.55 ± 0.45 μM) and UN (8.9 ± 1.0 vs. 11.6 ± 0.8 mM). Coadministration of DHA with MS-PPOH inhibited the production of EDPs, resulting in the significantly lower plasma levels of Cr (3.70 ± 1.35 μM) and UN (4.8 ± 1.8 mM) than those of the mice treated with DHA alone.
The 14 (15)-EET and 19 (20)-EDP Inhibited Inflammatory Cytokines in
Vivo. As expected, I/R treatment resulted in significant increase in plasma level of TNFα, IL-6, and MCP-1 (SI Appendix, Table  S2 ). Both coadministration of 14 (15) (Fig. 3K) . In addition, silencing RNA of GSK3β (shGSK3β) significantly inhibited, while constitutively active Ser9 of GSK3β (S9A) significantly promoted, the H/R-caused apoptosis of mRTECs compared with their respective controls. However, both 14 (15)-EET and 19 (20)-EDP failed to significantly modulate the H/Rcaused apoptosis of mRTECs after the transfection with shGSK3β or S9A (Fig. 3 L and M) . As shown in Fig. 3 B-E, all of the treatments insignificantly modified the protein expression of GSK3β (Fig. 3 B  and C) . However, H/R treatment resulted in a significant decrease in the protein expression of p-GSK3β in mRTECs compared with the control group, causing a significant reduction in the ratio of p-GSK3β/GSK3β (Fig. 3 B-E) . The treatment of 14 (15)-EET reversed the H/R-caused reduction in protein expression of p-GSK3β (Fig. 3D ) and the ratio of p-GSK3β/GSK3β (Fig. 3E) dose-dependently. In contrast, the administration of 19 (20)-EDP decreased the protein expression of p-GSK3β (Fig.  3I) , resulting in a lower ratio of p-GSK3β/GSK3β than that of H/R-control cells dose-dependently (Fig. 3J) . 
Discussion
This study reports that the epoxides of ω-3 and ω-6 PUFAs have opposite effects in I/R-caused kidney injury. We first showed that the administration of 19 (20)-EDP, the abundant metabolite of the ω-3 PUFA DHA, mediated largely by CYP2C and 2J, significantly shortened the survival of the mice with I/R-caused AKI (Fig. 1A) . This significantly shortened survival strongly indicates that 19 (20) Fig. S1 ) and accelerated the death of I/R AKI mice (Fig. 1A) . This hypothesis was also supported by the increases in plasma Cr and UN and renal NGAL caused by the administration of 19 (20) Fig. 2 A-C) . In addition, the coadministration of DHA with MS-PPOH that inhibits the production of EDPs enhances the beneficial effect of DHA in the attenuation of renal injury by histological examination, plasma Cr, and UN. All these facts support that 19 (20)-EDP aggravates renal injury in the murine model of I/R-caused AKI. In contrast, administration of 14 (15)-EET, the abundant epoxide metabolite of the ω-6 PUFA ARA, significantly prolonged the survival of I/R-caused AKI mice, which strongly suggests that treatment with 14 (15)-EET reduces the I/R-caused renal injury. This hypothesis was further supported by the histological examination of the kidney, which clearly showed the improvement of tubular dilation and brush border detachment by EET treatment. The increase in plasma Cr and UN and renal NGAL caused by I/R significantly decreased following the treatment with 14 (15)-EET, which supports the hypothesis. This beneficial decrease was even enhanced by the coadministration of 14 (15)-EET with TPPU that stabilized the endogenous EETs levels. In addition, coadministration of 14 (15)-EET with TPPU significantly compressed the dramatic increase in IL-6 caused by I/R (SI Appendix, Table S2 ) and improved the survival of the mice with I/R AKI (Fig. 1A) . All these facts support that 14 (15)-EET mitigates I/R-caused renal injury, which presents substantial proof supporting the previously reported studies that treatment with sEH inhibitors attenuates renal injury in AKI mice (13-15). (Fig. 1A) . This was consistent with the insignificant changes in plasma Cr ( Fig. 2A) and urea (Fig. 2B) and with the insignificant changes in EETs and EDP (Fig. 2 D and E and SI Appendix, Table S1 ) from the mice receiving coadministration of 14 (15) The epoxide metabolites of ω-3 PUFAs (e.g., EDPs) were reported sporadically regarding their biological functions although ω-3 PUFAs, such as DHA and eicosapentaenoic acid (EPA), as well as DHA-and EPA-enriched foods, have been reported and reviewed extensively to be antiinflammatory, cardio-protective, reno-protective, and tumor inhibitory (10, (19) (20) (21) (22) (23) (24) . Sharma et al. Table S1 ). A pilot study of 30 healthy people in this laboratory found the serum levels of 19 (20)-EDP ranging from 0.09 to 1.20 nM. Therefore, this study also raises a caution that, extrapolating from the murine data of this study, administration of DHA to AKI patients should be considered with care. Certainly such dietary supplementation should avoid the cointake of sEH inhibitors and sEH inhibitor-containing foods, which may blunt the beneficial effects of DHA, or even exacerbate the renal injury.
Unlike the less studied EDPs, EETs have been extensively reported to be antiinflammatory, analgesic, vaso-validative, and cardio-protective (25) (26) (27) . EETs were also regarded to be renoprotective in rodent and murine models of I/R-and cisplatincaused AKI (13) (14) (15) 28) . However, the reno-protective effect of EETs in previous studies was all conjectural based on the pharmacological intervention with either the administration of a sEH inhibitor or the targeted gene disruption of sEH (13) (14) (15) 28) . Although the results are reasonable, the direct evidence followed by monitoring in vivo levels of EETs is lacking. In addition, the sEH rapidly hydrolyzes all epoxy-fatty acids tested. Therefore, blocking of sEH by pharmacological intervention with a sEH inhibitor like TPPU or target gene disruption of sEH results in the significant increase in the epoxides of many PUFAs, including but not limited to, EETs, EDPs, epoxyoctadecamonoeneoic acids (epoxide metabolites of linoleic acid), and epoxyeicosatetraenoic acids (epoxide metabolites of EPA). It is difficult to distinguish EETs as reno-protective mediators from other epoxides. This study presents direct evidence that 14 (15)-EET alleviates the renal injury caused by I/R by administration of 14 (15)-EET alone. In addition, the fact that coadministration of 14 (15)-EET with TPPU stabilizes the endogenous 14 (15)-EET and enhances the reno-protection of 14 (15)-EET further testify to its reno-protective effect. This study suggests that the approaches to increasing endogenous 14 (15)-EET by treatment with 14 (15)-EET alone, and sEH inhibitors alone, as well as the combination or EET mimics are promising therapeutic and prophylactic strategies for AKI and possibly other kidney injuries.
Apoptosis of RTECs is a key step in the pathogenesis of I/Rcaused renal injury (29, 30) . Here, we test whether 14 (15)-EET and 19 (20)-EDP modulate the apoptosis of mRTECs in vitro in opposite ways. The mRTECs were treated with CoCl 2 to cause hypoxia followed by reoxygenation to mimic I/R-caused renal injury in vivo (31, 32) . The 14 (15)-EET significantly inhibited the H/R-caused mRTEC apoptosis in a positive dose-dependent manner while 19 (20)-EDP significantly promoted the H/R-caused mRTEC apoptosis dose-dependently (Fig. 3 A and F) . GSK3β has been found to be a key enzyme involved in kidney injury in AKI and inhibition of proliferative repair responses (16, 34) . The pathogenesis of kidney injury is accompanied by a significant reduction in the phosphorylation of GSK3β and a significant increase in the activity of GSK3β (18, 35) . Inhibition of GSK3β by both pharmacological interventions with chemical inhibitors and target gene deletion attenuates the kidney injury (17, 35, 36) . However, the role of GSK3β's activity in transducing the effects of epoxy fatty acids (e.g., EDPs and EETs) in kidney injury has not been established yet. We found that the protein expression of p-GSK3β in kidney tissues significantly decreased after I/R treatment, indicating an increase in the activity of GSK3β. Administration of 14 (15)-EET to AKI mice significantly up-regulated the protein expression of p-GSK3β in kidney tissues compared with those of I/R AKI mice, indicating a reduction in the activity of GSK3β. Coadministration of 14 (15)-EET with TPPU increased the circulating levels of 14 (15)-EET, but did not increase protein expression of p-GSK3β and the ratio of p-GSK3β/GSK3β compared with the mice treated with 14 (15)-EET alone. Possibly the mice treated with 14 (15)-EET alone achieved sufficient levels of EETs for the phosphorylation of GSK3β. Furthermore, in the mRTEC model, 14 (15)-EET significantly promoted the phosphorylation of GSK3β and repressed the activity of GSK3β, elucidating the inhibition of the H/R-caused apoptosis of mRTECs in vitro. In addition, coadministration of LiCl, a well-known inhibitor of GSK3β, with 14 (15)-EET resulted in an additive effect in the increase in protein expression of p-GSK3β (SI Appendix, Fig. S5 ) and in inhibiting the H/R-caused apoptosis of mRTECs, which was consistent with administration of 14 (15)-EET to the mRTECs post transfection with shGSK3β, and constitutively active S9A failed to modulate the H/R-caused cell apoptosis significantly (Fig. 3 L  and M) . These data strongly support that 14 (15)-EET inhibits the activity of GSK3β and contributes to its effect in reducing the apoptosis of RTECs and thus ameliorating the I/R-caused renal injury in vivo. Our finding in kidney is also consistent with previous findings that inactivation of GSK3β through increasing p-GSK3β contributes to the cardiac-protective effect of EETs (37-39). All these facts support that EETs have a protective effect on ischemia-caused cardiac and renal injury, which are both involved in the promotion of GSK3β phosphorylation.
In contrast, 19 (20)-EDP dose-dependently reduces the phosphorylation of GSK3β in mRTECs, consistent with its deleterious effect on H/R-caused mRTEC apoptosis in vitro and I/R-caused renal injury in vivo. However, administration of 19 (20)-EDP alone failed to decrease the phosphorylation of GSK3β in vivo. This may be due to the collective effects of the increased levels of EDP and EETs caused by treatment with 19 (20)-EDP alone (Fig. 2 D and E and SI Appendix, Table S1 ). In addition, coadministration of LiCl with 19 (20)-EDP to mRTECs resulted in a contradictory effect on H/R-caused apoptosis, consistent with the administration of 19 (20)-EDP to the mRTECs post transfection with shGSK3β, and constitutively active S9A failed to modulate the H/R-caused cell apoptosis significantly. These data suggest that 19 (20) -EDP induces the activity of GSK3β and contributes to its effect in promoting RTEC apoptosis and thus exacerbating the I/R-caused renal injury in vivo.
In short, this study demonstrates that the effects of epoxides of ω-3 and ω-6 PUFAs in kidney injury are the opposite: 14 (15)-EET mitigates, while 19 (20)-EDP aggravates, the I/R-caused kidney injury in a murine model. This may account, at least in part, for their opposite effects in modulation of the H/R-caused RTEC apoptosis, the phosphorylation of GSK3β, and their different metabolic stability. This study also provides AKI and other kidney disease patients with promising insights into treatments with ω-3 and ω-6 PUFAs and their epoxide metabolites for better recovery.
Materials and Methods
All animal experiments were performed according to protocols approved by the Animal Use and Care Committee of Shanghai Tenth People's Hospital, Tongji University School of Medicine. The use of human samples was approved by the independent ethics committee of Shanghai Tenth People's Hospital on February 29, 2016 . The serum for EDP analysis was the remaining sample after clinical use from the healthy volunteers who were clinically diagnosed in the Physical Examination Department of this hospital. All of the volunteers signed an informed consent statement to approve the use of their remaining sample. Ischemia/reperfusion of kidney was conducted according to a modified protocol of the previously reported procedure (40) . The group information on animal treatment is presented in Fig. 1 and SI Appendix, Table S4 . The details of materials, experimental protocols, and analytical methods are presented in SI Appendix.
